Literature DB >> 1428226

Lung cancer following Hodgkin's disease: a case-control study.

J M Kaldor1, N E Day, J Bell, E A Clarke, F Langmark, S Karjalainen, P Band, D Pedersen, W Choi, V Blair.   

Abstract

It is recognized that survivors of Hodgkin's disease are at a substantially increased risk of lung cancer. A collaborative group of population-based cancer registries and major treatment centers carried out a case-control study, in which 98 cases of lung cancer were identified in patients who had survived at least 1 year following a diagnosis of Hodgkin's disease. A total of 259 matched controls were selected from patients with Hodgkin's disease who did not develop subsequent lung cancer, and for both cases and controls detailed information was abstracted from medical records concerning stage and treatment of Hodgkin's disease. Patients treated with chemotherapy alone had about twice the risk of developing lung cancer than those treated by radiotherapy alone or both modalities. There was no increase in risk with cumulative number of cycles of chemotherapy. Among patients treated with radiotherapy alone, there was an increase in risk related to estimated radiation dose to the lung. There was also a strong association between cigarette smoking and the risk of lung cancer. The finding of a higher risk following chemotherapy than following radiotherapy was unexpected, but could not be explained by any identified methodological flaws. A plausible inference from the study is that all forms of Hodgkin's disease therapy are carcinogenic to the lung and that, in particular, chemotherapy is associated with an increase in risk which is at least comparable to and perhaps higher than the risk produced by radiotherapy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1428226     DOI: 10.1002/ijc.2910520502

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

1.  Pleomorphic carcinoma of the lung with mediastinal extension following malignant lymphoma: report of a case.

Authors:  Takahiro Nakajima; Toshihiko Iizasa; Akira Iyoda; Kenzo Hiroshima; Kazuhiro Yasufuku; Masako Chiyo; Takashi Anayama; Hidemi Suzuki; Kiyoshi Shibuya; Hidemi Ohwada; Takehiko Fujisawa
Journal:  Surg Today       Date:  2005       Impact factor: 2.549

Review 2.  Increased risk of second lung cancer in Hodgkin's lymphoma survivors: a meta-analysis.

Authors:  Ezzeldin M Ibrahim; Ghieth A Kazkaz; Khaled M Abouelkhair; Mubarak M Al-Mansour; Turki M Al-Fayea; Meteb Al-Foheidi; Ali M Bayer; Osama A Elmasri
Journal:  Lung       Date:  2012-10-06       Impact factor: 2.584

Review 3.  Chemotherapy, radiotherapy and combined modality for Hodgkin's disease, with emphasis on second cancer risk.

Authors:  J G Franklin; M D Paus; A Pluetschow; L Specht
Journal:  Cochrane Database Syst Rev       Date:  2005-10-19

Review 4.  Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis.

Authors:  Jeremy Franklin; Dennis A Eichenauer; Ingrid Becker; Ina Monsef; Andreas Engert
Journal:  Cochrane Database Syst Rev       Date:  2017-09-13

5.  Lung cancer and other second neoplasms after treatment of Hodgkin lymphoma.

Authors:  E Almagro-Casado; A Sánchez; B Cantos; C Salas; D Pérez-Callejo; M Provencio
Journal:  Clin Transl Oncol       Date:  2015-11-03       Impact factor: 3.405

6.  Adjuvant radiotherapy for breast cancer as a risk factor for the development of lung cancer.

Authors:  P H Wiernik; N T Sklarin; J P Dutcher; J A Sparano; E S Greenwald
Journal:  Med Oncol       Date:  1994       Impact factor: 3.064

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.